EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Differences in Early Tacrolimus Exposure in Kidney Transplant Recipients With and Without CYP3A5 Genotype‐Guided Tacrolimus Dosing

Amy L Pasternak iD, Jenna Schwartz, Brett Vanderwerff, Sebastian Zöllner, Danielle J Haakinson, Mona Doshi, Jeong M Park

Clinical and Translational Science · 2026

DOI: 10.1111/cts.70726 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Amy L Pasternak und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Tacrolimus, Cytochrome P-450 CYP3A, Kidney Transplantation, Immunosuppressive Agents. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CYP3A5 genotype is a known predictor of tacrolimus dose requirements. This single‐center retrospective study evaluated the impact of CYP3A5 genotype‐guided dosing, implemented at our institution in 10/2023, on early tacrolimus exposure. Patients were included if they were adult kidney transplant recipients between 7/2014 and 10/2024; patients in the weight‐based cohort had research CYP3A5 genotypes in the institutional research biorepository and the genotype‐guided cohort had a clinical CYP3A5 genotype available at transplant. The primary outcome was time to therapeutic steady‐state (TSS) and secondary outcomes included classification of trough concentration on postoperative‐day (POD) 2, tacrolimus dose at TSS, and tacrolimus intrapatient variability (IPV) at 14‐ and 30‐day post‐transplant. Outcomes were also evaluated within each CYP3A5 phenotype and a per‐protocol evaluation. Outcomes were compared via Mann–Whitney U, Chi‐squared, or Fischer's exact tests. The median TSS was decreased in CYP3A5 normal metabolizers (6.0 days (3.0–6.0) vs. 16.0 days (8.0–16.0); p = 0.01) and CYP3A5 intermediate metabolizers had significantly fewer subtherapeutic troughs on POD2 (25.8% vs. 61.1%; p = 0.01) in the genotype‐guided cohort. CYP3A5 poor metabolizers were more likely to have a subtherapeutic trough on POD2 in the genotype‐guided cohort. The time below therapeutic range in the first 14 days was significantly reduced for CYP3A5 intermediate metabolizers who received per‐protocol, genotype‐guided dosing. The TSS dose did not differ between the cohorts but was lower than the genotype‐guided protocol dosing. CYP3A5 genotype‐guided dosing reduced the likelihood of early subtherapeutic exposure in CYP3A5 normal and intermediate metabolizers. Refinement of the genotype‐guided dosing strategy may help further improve early tacrolimus exposure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TacrolimusCytochrome P-450 CYP3AKidney TransplantationImmunosuppressive AgentsGraft RejectionHumansFemaleMaleMiddle AgedRetrospective StudiesAdultGenotypePharmacogenomic VariantsPharmacogenomic Testing

Stichwörter der Autor:innen

CYP3A5implementationpersonalized dosingpharmacogeneticstacrolimus

Substanzen

TacrolimusCytochrome P-450 CYP3ACYP3A5 protein, humanImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.
  • Department of Pharmacy, Michigan Medicine, Ann Arbor, Michigan, USA.
  • Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.
  • Department of Surgery, Michigan Medicine, Ann Arbor, Michigan, USA.
  • Department of Internal Medicine, Michigan Medicine, Ann Arbor, Michigan, USA.

ORCID-Profile: Amy L Pasternak

Zitieren

APA

Pasternak, A. L., Schwartz, J., Vanderwerff, B., Zöllner, S., Haakinson, D. J., Doshi, M., & Park, J. M. (2026). Differences in Early Tacrolimus Exposure in Kidney Transplant Recipients With and Without CYP3A5 Genotype‐Guided Tacrolimus Dosing. Clinical and Translational Science. https://doi.org/10.1111/cts.70726

Vancouver

Pasternak AL, Schwartz J, Vanderwerff B, Zöllner S, Haakinson DJ, Doshi M, et al. Differences in Early Tacrolimus Exposure in Kidney Transplant Recipients With and Without CYP3A5 Genotype‐Guided Tacrolimus Dosing. Clinical and Translational Science. 2026. doi:10.1111/cts.70726

BibTeX
@article{Pasternak2026,
  author = {Pasternak, Amy L and Schwartz, Jenna and Vanderwerff, Brett and Zöllner, Sebastian and Haakinson, Danielle J and Doshi, Mona and Park, Jeong M},
  title = {Differences in Early Tacrolimus Exposure in Kidney Transplant Recipients With and Without CYP3A5 Genotype‐Guided Tacrolimus Dosing},
  journal = {Clinical and Translational Science},
  year = {2026},
  doi = {10.1111/cts.70726}
}
Kostenlos starten →